Abstract: A display device includes a first semiconductor layer disposed on a substrate; a first insulating layer disposed on the first semiconductor layer; a scan line disposed on the first insulating layer; a second insulating layer on the scan line; an inverted scan line on the second insulating layer; a third insulating layer disposed on the inverted scan line; a second semiconductor layer disposed on the third insulating layer; a fourth insulating layer disposed on the second semiconductor layer; an initializing voltage line disposed on the fourth insulating layer and overlapping the scan line; a first transistor including a channel disposed in the first semiconductor layer and receiving a gate signal through the scan line; and a second transistor including a channel disposed in the second semiconductor layer and receiving a gate signal through the inverted scan line.

Abstract: The present invention relates to a multi-component host material and an organic electroluminescent device comprising the same. By comprising a specific combination of the multi-component host compounds, the organic electroluminescent device according to the present invention can provide high luminous efficiency and excellent lifespan characteristics.

Abstract: The present invention relates a method for maximizing the coronavirus killing activity of high-density lipoproteins, and a pharmaceutical composition for preventing or treating COVID-19. As identified by the present inventors, non-glycated normal high-density lipoproteins (HDLs) exhibit killing activity against coronavirus (SARS-Cov-2) that is superior to that of glycated HDLs, and thus a pharmaceutical composition for preventing and treating COVID-19, containing non-glycated native HDLs as an active ingredient, is provided. In addition, the present invention is useful since a method for maximizing the coronavirus killing activity by using an HDL glycation inhibitor, on the basis of the identification by the present inventors, can be provided and a method for screening for a pharmaceutical composition for preventing and treating COVID-19 by evaluating the degree of HDL glycosylation inhibition of candidate drugs can be provided.

Abstract: Disclosed is a light emitting display device configured such that a power line that supplies source voltage from a pad unit and a cathode are connected to each other using a trench provided in a planarization layer so as to have a linear shape, whereby reliability in prevention of permeation is improved, an area that protrudes and is processed for a connection portion is minimized, whereby a non-display area is reduced, a cathode connection portion is located in a wide area to increase a heat generation path, whereby reliability is improved.

Abstract: The disclosure relates to an organic light emitting display device that can detect a defect in a scan transistor in the device in which the scan transistor and a sensing transistor simultaneously operate, and the device includes: an OLED in a subpixel; a driving transistor connected between the OLED and a driving voltage line; a scan transistor connected between a first node through which a data voltage is applied to the driving transistor and a data line; a sensing transistor connected between a second node between the driving transistor, the OLED, and a reference voltage line; and a defect detector for applying the data voltage in a state in which both the scan transistor and the sensing transistor are turned off and then detecting an amount of charges charged in a parasitic capacitor of the OLED to determine whether the scan transistor is defective due to foreign substances.

Abstract: The disclosure relates to an organic light emitting display device that can detect a defect in a scan transistor in the device in which the scan transistor and a sensing transistor simultaneously operate, and the device includes: an OLED in a subpixel; a driving transistor connected between the OLED and a driving voltage line; a scan transistor connected between a first node through which a data voltage is applied to the driving transistor and a data line; a sensing transistor connected between a second node between the driving transistor, the OLED, and a reference voltage line; and a defect detector for applying the data voltage in a state in which both the scan transistor and the sensing transistor are turned off and then detecting an amount of charges charged in a parasitic capacitor of the OLED to determine whether the scan transistor is defective due to foreign substances.

Abstract: Provided is a rapamycin formulation using a recombinant high-density lipoprotein including apolipoprotein mutant, the rapamycin formulation in which solubility of rapamycin and medical use, such as aging suppression and arteriosclerosis suppression, are improved by using recombinant high-density lipoprotein including apolipoprotein A-I and its mutant V156K.

Abstract: Provided is a rapamycin formulation using a recombinant high-density lipoprotein including apolipoprotein mutant, the rapamycin formulation in which solubility of rapamycin and medical use, such as aging suppression and arteriosclerosis suppression, are improved by using recombinant high-density lipoprotein including apolipoprotein A-I and its mutant V156K.

Abstract: Disclosed herein are method and kit for diagnosing acute myocardial infarction which is capable of predicting and diagnosing whether coronary artery disease is proceed to myocardial infarction or not by using an increase in triglyceride level in high density lipoprotein (HDL) or low density lipoprotein (LDL), a decrease in cholesterol level in HDL, increase of interleukin-6, CETP (cholesteryl ester transfer protein) and apo (apolipoprotein) C-III as a biomarker that are characteristic changes occurred only in sera of myocardial infarction patients among patients with coronary artery disease.

Abstract: The proapoA-I mutants of the present invention exhibit superior LDL-antioxidant activities over the wild-type proapoA-I and higher efficiencies for delivering cholesterol to hepatocytes than the previously reported apoA-I-R173C, and thus they can be effectively used for prevention and treatment of hyperlipidemia or atherosclerosis.

Abstract: The proapoA-I mutants of the present invention exhibit superior LDL-antioxidant activities over the wild-type proapoA-I and higher efficiencies for delivering cholesterol to hepatocytes than the previously reported apoA-I-R173C, and thus they can be effectively used for prevention and treatment of hyperlipidemia or atherosclerosis.

Abstract: A peptide consisting of the following amino acid sequence, or an analogue or a fragment thereof, has an inhibitory activity on cholesteryl ester transfer protein:Glu Asp Thr Ser Pro Glu Asp Lys Met Gln Asp Tyr Val Lys Gln Ala Thr Arg Thr Ala Gln Asp Ala Leu Thr Ser Val Lys.